Skip to search formSkip to main contentSkip to account menu

pagibaximab

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Introduction: Advances in modern medicine have given very low birth weight (VLBW) infants a better chance of survival; however… 
Highly Cited
2011
Highly Cited
2011
BACKGROUND: Pagibaximab, a human chimeric monoclonal antibody developed against lipoteichoic acid, was effective against… 
Highly Cited
2009
Highly Cited
2009
ABSTRACT Staphylococcal sepsis is a major cause of morbidity and mortality in very-low-birth-weight (VLBW) infants. A human… 
Review
2009
Review
2009
  • P. Shah, D. Kaufman
  • The Cochrane database of systematic reviews
  • 2009
  • Corpus ID: 205183011
BACKGROUND Nosocomial infection is a major problem affecting the immediate health and long-term outcome of preterm and very low… 
2008
2008
The ability to measure the opsonic activity of antibody may be critical in choosing among potential therapeutic candidates. It… 
Review
2007
Review
2007
  • L. Weisman
  • Archives de pediatrie : organe officiel de la…
  • 2007
  • Corpus ID: 2435425